A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults)
详细信息 查看全文
- 作者：Scott Pattersona ; Scott.Patterson@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Chris Webberb ; Chris.Webber@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Michael Pattonb ; michael.patton@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Wayne Drewsc ; wayne.drews@inventivhealth.com" class="auth_mail" title="E-mail the corresponding author ; Susanne M. Huijtsd ; 1 ; S.M.Huijts@umcutrecht.nl" class="auth_mail" title="E-mail the corresponding author ; Marieke Bolkenbaasd ; m.bolkenbaas-2@umcutrecht.nl" class="auth_mail" title="E-mail the corresponding author ; William C. Grubere ; bill.gruber@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Daniel A. Scotte ; dan.scott@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; Marc J.M. Bontend ; M.J.M.Bonten@umcutrecht.nl" class="auth_mail" title="E-mail the corresponding author ; for the CAPiTA Study Group
- 关键词：Community-acquired pneumonia ; Invasive pneumococcal disease ; PCV13 ; Pneumococcal conjugate vaccine ; Persistence of vaccine efficacy
- 刊名：Trials in Vaccinology
- 出版年：2016
- 出版时间：2016
- 年：2016
- 卷：5
- 期：Complete
- 页码：92-96
- 全文大小：304 K
文摘
- class="listitem" id="list_l0005">
- class="label">•
Analysis of PCV13 vaccine efficacy against community-acquired pneumonia in older adults.
- class="label">•
Significant difference in disease-free survival in PCV13 recipients compared with placebo.
- class="label">•
PCV13 was protective against vaccine-type disease over the 5-year study duration.
- class="label">•
No waning of vaccine efficacy was observed.